NYU Data Catalog

NYU Dataset

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia

UID: 10111
Author(s): Robert C. Smith*, Revital Amiaz, Tian-Mei Si, Lawrence Maayan, Hua Jin...
* Corresponding Author
Description
Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains. Varenicline is a partial nicotinic agonist which is effects as an anti-smoking drug in cigarette smokers, although concerns have been raised about potential psychiatric side-effects. This data is from a double-blind placebo controlled study in 87 schizophrenic smokers to evaluate the effect of varenicline on measures of smoking, cognition, psychiatric symptoms, and side-effects in schizophrenic patients who are cigarette smokers.
Timeframe
2012
Subject of Study
Homo sapiens
Subject Domain
Chronic Disease
Mental Health
Risk Factors
Population Age
Adult (19 years - 64 years)
Subject Gender
Male
Female
Keywords
Chronic Disease
Cognitive Disorders
Depression
Mental Health
Nicotinic Receptors
Risk Factors
Schizophrenia
Smoking
Smoking Cessation
Tobacco Use
Varenicline

Access

Restrictions
Free to All
Instructions
Data and associated documentation are available on the figshare repository.
Access via figshare

Data and Protocol

Associated Publications
Smith RC, Amiaz R, Si TM et al. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blong Randomized Trial. PLoS One. 2016 Jan 5;11(1):e0143490.
Data Type
Clinical Measures
Study Type
Interventional
Dataset Format(s)
SPSS
Other Resources
ClinicalTrials.gov

NCT00802919